The committee favors marketing the infliximab biosimilar product Zessly for treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis.
International Approvals
https://ift.tt/2pBPW3b
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου